1、1/October 2022 Pharma Intelligence UK Ltd 2022(Unauthorized photocopying prohibited.)As pharma dealmakers,biotech executives,and investors all convene in Leipzig,Germany for the first in-person BIO-Europe in three years,the life sciences landscape is in a very different place.European companies play

2、ed a leading role in the pandemic response,from developing innovative new vaccine technologies,to manufacturing billions of doses,through to an unprecedented scale up in diagnostic capabilities.This occurred against the backdrop of record levels of investment in the sector,spanning both public money

3、 and venture capital,supporting the promise of exciting new drug development platforms and therapeutic capabilities.It has certainly been a busy time in the business development world,although this should not distract or detract from the persisting,fundamental challenges that drug developers in Euro

4、pe face.The pharmaceutical industry is very much global,and innovation is a critical export.Europe is losing ground at this level,with a declining stake in global R&D.As this white paper shows,Europes innovative pipeline has reached a plateau,and is underexposed to high-growth areas such as oncology

5、,cell and gene therapy.While investment is at all-time highs,this is targeted towards mature companies,rather than entrepreneurial start-ups that are more at home in the US.Pipelines and partnerships are the lifeblood of the pharmaceutical industry and dictate its The State of Innovation in EuropeDa

6、niel Chancellor Thought Leadership and Consulting Director,CitelineIntroduction2/October 2022 Pharma Intelligence UK Ltd 2022(Unauthorized photocopying prohibited.)future direction.With a declining stake in these,Europe runs the risk of the pharmaceutical industry being increasingly molded in the im